Question to the Department of Health and Social Care:

To ask the Secretary of State for Health and Social Care, how many myeloma patients are receiving a fourth line treatment; and what proportion of those patients are being treated with isatuximab in combination with pomalidomide and dexamethasone.

Information on the number of myeloma patients receiving a fourth line treatment is not held centrally. However, the following table shows the number of patients notified to receive isatuximab, in combination with pomalidomide and dexamethasone, in 2021, 2022, 2023 and from January to July of 2024:

Source: NHS England.
Note: not all patients will necessarily go on to receive the treatment itself.